Acute and long-term effects of cannabis use: A review

Current Pharmaceutical Design

Volumn 20, Issue 25, 2014, Pages 4112-4118

  Karila, Laurent ^a   Roux, Perrine ^b   Rolland, Benjamin ^c   Benyamina, Amine ^a   Reynaud, Michel ^a   Aubin, Henri Jean ^a   Lançon, Christophe ^d  

^a HÔPITAL PAUL BROUSSE   (France)

^b AIX MARSEILLE UNIV   (France)

^c UNIV LILLE   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

Author keywords

Acute effects; Addiction; And cannabis use disorders; Cannabinoids; Cannabis; Dependence; Long term effects; Marijuana; THC

Indexed keywords

AMOTIVATIONAL SYNDROME; ARTICLE; BEHAVIOR DISORDER; CANNABIS SMOKING; CANNABIS USE; CANNABIS USE DISORDER; CANNABIS WITHDRAWAL SYNDROME; COGNITIVE DEFECT; DEPERSONALIZATION; DIGESTIVE SYSTEM DISEASE; GYNECOLOGIC DISEASE; HUMAN; LONG TERM EXPOSURE; MENTAL DISEASE; METABOLIC DISORDER; MORTALITY; NEOPLASM; PERFORMANCE ANXIETY; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RESPIRATORY TRACT DISEASE; SKIN DISEASE; SOCIAL PSYCHOLOGY; SUBSTANCE ABUSE; SUICIDAL IDEATION; TRAFFIC ACCIDENT; WITHDRAWAL SYNDROME; ADDICTION; CHEMICALLY INDUCED; DRUG USE; PATHOPHYSIOLOGY; PSYCHOLOGY; PUBLIC HEALTH; STATISTICS AND NUMERICAL DATA;

CANNABIS; MEDICAL CANNABIS;

BEHAVIOR, ADDICTIVE; CANNABIS; DRUG USERS; HUMANS; MEDICAL MARIJUANA; PUBLIC HEALTH; SUBSTANCE-RELATED DISORDERS;

EID: 84904060075     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990620     Document Type: Article

References (121)

1. Hall W, Solowij N. Adverse effects of cannabis. Lancet 1998; 352(9140): 1611-1616.
2. EMCDDA. European Monitoring Centre for Drugs and Drug Addiction - Annual report 2012: the state of the drugs problem in Europe. Luxembourg: Publications Office of the European Union 2012.
3. SAMHSA. Substance Abuse and Mental Health Services Administration, Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-41, HHS Publication No. (SMA) 11-4658. Rockville, MD: Substance Abuse and Mental Health Services Administration 2011 2011.
4. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. National press release, More good news on teen smoking: Rates at or near record lows. University of Michigan News Service, Ann Arbor, 23 pp. 2008.
5. SAMHSA. Substance Abuse and Mental Health Services Administration. (2009). Results from the 2008 National Survey on Drug Use and Health: National Findings (Office of Applied Studies, NSDUH Series H-36, HHS Publication No. SMA 09-4434). Rockville, MD 2009.
6. Hibell B, Guttormsson U, Ahlström S, et al. The 2011 ESPAD report: substance use among students in 36 European countries, Swedish Council for Information on Alcohol and Other Drugs, Stockholm, Sweden 2012.
7. Copeland J, Swift W. Cannabis use disorder: epidemiology and management. Int Rev Psychiatry 2009 Apr; 21(2): 96-103.
8. UNODC. World drug report 2009, United Nations Office on Drugs and Crime, Vienna 2009.
9. Appendino G, Chianese G, Taglialatela-Scafati O. Cannabinoids: occurrence and medicinal chemistry. Curr Med Chem 2011; 18: 1085-1099.
10. Perez-Reyes M, White W, McDonald S, et al. The pharmacologic effects of daily marijuana smoking in humans. Pharmacol Biochem Behav 1991; 40: 691-694.
11. Sharma P, Murthy P, Bharath MM. Chemistry, metabolism, and toxicology of cannabis: clinical implications. Iran J Psychiatry 2012; 7(4): 149-156.
12. Bhattacharyya S, Morrison PD, Fusar-Poli P, et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 2010; 35(3): 764-774.
13. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 2008; 153(2): 199-215.
14. Costa B. On the pharmacological properties of Delta9-tetrahydrocannabinol (THC). Chem Biodivers 2007; 4(8): 1664-1677.
15. Martin-Santos R, Crippa JA, Batalla A, et al. Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers. Curr Pharm Des 2012; 18(32): 4966-4979.
16. Zuardi AW, Crippa JA, Hallak JE, et al. A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. Curr Pharm Des 2012; 18(32): 5131-5140.
17. Guindon J, Hohmann AG. The endocannabinoid system and pain. CNS Neurol Disord Drug Targets 2009; 8(6): 403-421.
18. Jain R, Balhara YP. Neurobiology of cannabis addiction. Indian J Physiol Pharmacol 2008; 52(3): 217-232.
19. Costentin J. Neuropsychopharmacology of delta-9-tetrahydrocannabinol. Ann Pharm Fr 2008 Aug; 66(4): 219-231.
20. Guindon J, Hohmann AG. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol 2008; 153(2): 319-334.
21. Georgiades K, Boyle MH. Adolescent tobacco and cannabis use: young adult outcomes from the Ontario Child Health Study. J Child Psychol Psychiatry 2007; 48(7): 724-731.
22. Schneider M. Puberty as a highly vulnerable developmental period for the consequences of cannabis exposure. Addict Biol 2008; 13(2): 253-263.
23. Blakemore SJ. Teenage kicks: cannabis and the adolescent brain. Lancet 2013; 381(9870): 888-889.
24. Shrubb R. The effects of cannabis on mental health. Ment Health Today 2012 Nov-Dec: 23.
25. Hall W. The adverse health effects of cannabis use: what are they, and what are their implications for policy? Int J Drug Policy 2009; 20(6): 458-466.
26. Crippa JA, Derenusson GN, Chagas MH, et al. Pharmacological interventions in the treatment of the acute effects of cannabis: a systematic review of literature. Harm Reduct J 2012; 9(1): 7.
27. Johnson BA. Psychopharmacological effects of cannabis. Br J Hosp Med 1990; 43(2): 114-116, 8-20, 22.
28. Johns A. Psychiatric effects of cannabis. Br J Psychiatry 2001; 178: 116-122.
29. Martin-Santos R, Crippa J, Batalla A, et al. Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers. Curr Pharm Des 2012; 18(32): 4966-4979.
30. D'Souza DC. Cannabinoids and psychosis. Int Rev Neurobiol 2007; 78: 289-326.
31. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007; 370(9584): 319-328.
32. Montgomery C, Seddon AL, Fisk JE, Murphy PN, Jansari A. Cannabis-related deficits in real-world memory. Hum Psychopharmacol 2012; 27(2): 217-225.
33. Fisk JE, Montgomery C. Real-world memory and executive processes in cannabis users and non-users. J Psychopharmacol 2008; 22(7): 727-736.
34. Yucel M, Lubman DI, Solowij N, Brewer WJ. Understanding drug addiction: a neuropsychological perspective. Aust N Z J Psychiatry 2007; 41(12): 957-968.
35. Karila L, Vignau J, Alter C, Reynaud M. [Acute and chronic cognitive disorders caused by cannabis use]. Rev Prat 2005; 55(1): 23-26; discussion 7-9.
36. Karila L, Reynaud M. Cognitive disorders and chronic use of cannabis. Ann Med Interne (Paris) 2003; 154 Spec No 1: S58-S64.
37. Bedard M, Dubois S, Weaver B. The impact of cannabis on driving. Can J Public Health 2007; 98(1): 6-11.
38. Asbridge M, Poulin C, Donato A. Motor vehicle collision risk and driving under the influence of cannabis: evidence from adolescents in Atlantic Canada. Accid Anal Prev 2005; 37(6): 1025-1034.
39. Asbridge M, Hayden JA, Cartwright JL. Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. BMJ 2012; 344: e536.
40. APA. Diagnostic and Statistical Manual of Mental Disorders, (Dsm-5). Association AP, editor: American Psychiatric Publishing; 2013.
41. Dennis M, Babor TF, Roebuck MC, Donaldson J. Changing the focus: the case for recognizing and treating cannabis use disorders. Addiction 2002; 97 Suppl 1: 4-15.
42. Ream GL, Benoit E, Johnson BD, Dunlap E. Smoking tobacco along with marijuana increases symptoms of cannabis dependence. Drug Alcohol Depend 2008; 95(3): 199-208.
43. APA. Diagnostic and statistical manual of mental disorders - Fifth Edition (DSM-5) - American Psychiatric Publishing, Washington DC 2013.
44. Budney AJ, Hughes JR. The cannabis withdrawal syndrome. Curr Opin Psychiatry 2006; 19(3): 233-238.
45. Smith NT. A review of the published literature into cannabis withdrawal symptoms in human users. Addiction 2002; 97(6): 621-632.
46. Gorelick DA, Levin KH, Copersino ML, et al. Diagnostic criteria for cannabis withdrawal syndrome. Drug Alcohol Depend 2012; 123(1-3): 141-147.
47. Budney AJ, Hughes JR, Moore BA, Vandrey R. Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry 2004; 161(11): 1967-1977.
48. Allsop DJ, Copeland J, Norberg MM, et al. Quantifying the clinical significance of cannabis withdrawal. PLoS One 2012; 7(9): e44864.
49. Grover S, Basu D. Cannabis and psychopathology: update 2004. Indian J Psychiatry 2004; 46(4): 299-309.
50. Negrete JC, Knapp WP, Douglas DE, Smith WB. Cannabis affects the severity of schizophrenic symptoms: results of a clinical survey. Psychol Med 1986; 16(3): 515-520.
51. Moran C. Depersonalization and agoraphobia associated with marijuana use. Br J Med Psychol 1986; 59 (Pt 2): 187-196.
52. Spiegel D, Loewenstein RJ, Lewis-Fernandez R, et al. Dissociative disorders in DSM-5. Depress Anxiety 2011; 28(12): E17-E45.
53. Szymanski H. Prolonged depersonalisation after marijuana use. Am J Psychiatry 1981; 138: 231-233.
54. Keshavan M, Lishman W. Prolonged Depersonalization Following Cannabis Abuse. British Journal of Addiction 1986; 81(1): 140-142.
55. Di Forti M, Morrison PD, Butt A, Murray RM. Cannabis use and psychiatric and cogitive disorders: the chicken or the egg? Curr Opin Psychiatry 2007; 20(3): 228-234.
56. Winklbaur B, Ebner N, Sachs G, Thau K, Fischer G. Substance abuse in patients with schizophrenia. Dialogues Clin Neurosci 2006; 8(1): 37-43.
57. Lev-Ran S, Le Foll B, McKenzie K, George TP, Rehm J. Cannabis use and cannabis use disorders among individuals with mental illness. Compr Psychiatry 2013 Jan 30.
58. Hayatbakhsh MR, McGee TR, Bor W, Najman JM, Jamrozik K, Mamun AA. Child and adolescent externalizing behavior and cannabis use disorders in early adulthood: an Australian prospective birth cohort study. Addict Behav 2008; 33(3): 422-438.
59. Wittchen HU, Frohlich C, Behrendt S, et al. Cannabis use and cannabis use disorders and their relationship to mental disorders: a 10-year prospective-longitudinal community study in adolescents. Drug Alcohol Depend 2007; 88 Suppl 1: S60-S70.
60. Zullino DF, Rathelot T, Khazaal Y. Cannabis and psychosis. Lancet 2007; 370(9598): 1540.
61. Zammit S, Moore TH, Lingford-Hughes A, et al. Effects of cannabis use on outcomes of psychotic disorders: systematic review. Br J Psychiatry 2008; 193(5): 357-363.
62. Casadio P, Fernandes C, Murray RM, Di Forti M. Cannabis use in young people: the risk for schizophrenia. Neurosci Biobehav Rev 2011; 35(8): 1779-1787.
63. Shrivastava A, Johnston M, Terpstra K, Bureau Y. Pathways to Psychosis in Cannabis Abuse. Clin Schizophr Relat Psychoses 2013; 14: 1-18.
64. Kuepper R, van Os J, Lieb R, Wittchen HU, Henquet C. Do cannabis and urbanicity co-participate in causing psychosis? Evidence from a 10-year follow-up cohort study. Psychol Med 2011; 41(10): 2121-2129.
65. Kuepper R, van Os J, Lieb R, Wittchen HU, Hofler M, Henquet C. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ 2011; 342: d738.
66. Large M, Sharma S, Compton MT, Slade T, Nielssen O. Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Arch Gen Psychiatry 2011; 68(6): 555-561.
67. Koskinen J, Lohonen J, Koponen H, Isohanni M, Miettunen J. Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophr Bull 2010; 36(6): 1115-1130.
68. Myles N, Newall H, Nielssen O, Large M. The association between cannabis use and earlier age at onset of schizophrenia and other psychoses: meta-analysis of possible confounding factors. Curr Pharm Des 2012; 18(32): 5055-5069.
69. Evins AE, Green AI, Kane JM, Murray RM. The effect of marijuana use on the risk for schizophrenia. J Clin Psychiatry 2012; 73(11): 1463-1468.
70. Reece AS. Chronic toxicology of cannabis. Clin Toxicol (Phila) 2009; 47(6): 517-524.
71. Price C, Hemmingsson T, Lewis G, Zammit S, Allebeck P. Cannabis and suicide: longitudinal study. Br J Psychiatry 2009; 195(6): 492-497.
72. Serafini G, Pompili M, Innamorati M, Rihmer Z, Sher L, Girardi P. Can cannabis increase the suicide risk in psychosis? A critical review. Curr Pharm Des 2012; 18(32): 5165-5187.
73. Crippa JA, Zuardi AW, Martin-Santos R, et al. Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol 2009; 24(7): 515-523.
74. Buckner JD, Schmidt NB, Bobadilla L, Taylor J. Social anxiety and problematic cannabis use: evaluating the moderating role of stress reactivity and perceived coping. Behav Res Ther 2006; 44(7): 1007-1015.
75. Buckner J, Schmidt N, Lang A, et al. Specificity of social anxiety disorder as a risk factor for alcohol and cannabis dependence. J Psychiatr Res, 2008; 42(3): 230-239.
76. Lev-Ran S, Le Foll B, McKenzie K, George TP, Rehm J. Bipolar disorder and co-occurring cannabis use disorders: Characteristics, co-morbidities and clinical correlates. Psychiatry Res 2013 Jan 9.
77. Iversen L. Long-term effects of exposure to cannabis. Curr Opin Pharmacol 2005; 5(1): 69-72.
78. Pope HG, Jr., Gruber AJ, Yurgelun-Todd D. Residual neuropsychologic effects of cannabis. Curr Psychiatry Rep 2001; 3(6): 507-512.
79. Pope HG, Jr., Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D. Cognitive measures in long-term cannabis users. J Clin Pharmacol 2002; 42(11 Suppl): 41S-47S.
80. Pope HG, Jr., Gruber AJ, Hudson JI, Cohane G, Huestis MA, Yurgelun-Todd D. Early-onset cannabis use and cognitive deficits: what is the nature of the association? Drug Alcohol Depend 2003; 69(3): 303-310.
81. Solowij N. Do cognitive impairments recover following cessation of cannabis use? Life Sci 1995; 56(23-24): 2119-2126.
82. Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RS, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci USA 2012; 109(40): E2657-E2664.
83. Solowij N, Pesa N. Cognitive abnormalities and cannabis use. Rev Bras Psiquiatr 2010; 32 Suppl 1: S31-S40.
84. Tait RJ, Mackinnon A, Christensen H. Cannabis use and cognitive function: 8-year trajectory in a young adult cohort. Addiction 2011; 106(12): 2195-2203.
85. Crean RD, Crane NA, Mason BJ. An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. J Addict Med 2011; 5(1): 1-8.
86. Pope HG, Jr., Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry 2001; 58(10): 909-915.
87. Grant J, Chamberlain S, Schreiber L, Odlaug B. Neuropsychological deficits associated with cannabis use in young adults. Drug Alcohol Depend 2012 121((1-2)): 159-162.
88. Bolla KI, Eldreth DA, Matochik JA, Cadet JL. Neural substrates of faulty decision-making in abstinent marijuana users. Neuroimage 2005; 26(2): 480-492.
89. Schreiner AM, Dunn ME. Residual effects of cannabis use on neurocognitive performance after prolonged abstinence: a meta-analysis. Exp Clin Psychopharmacol 2012; 20(5): 420-429.
90. Rawal SY, Tatakis DN, Tipton DA. Periodontal and oral manifestations of marijuana use. J Tenn Dent Assoc 2012; 92(2): 26-31; quiz -2.
91. Hezode C, Roudot-Thoraval F, Nguyen S, et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 2005; 42(1): 63-71.
92. Galli JA, Sawaya RA, Friedenberg FK. Cannabinoid hyperemesis syndrome. Curr Drug Abuse Rev 2011; 4(4): 241-249.
93. Nicolson SE, Denysenko L, Mulcare JL, Vito JP, Chabon B. Cannabinoid hyperemesis syndrome: a case series and review of previous reports. Psychosomatics 2012; 53(3): 212-219.
94. Sontineni SP, Chaudhary S, Sontineni V, Lanspa SJ. Cannabinoid hyperemesis syndrome: clinical diagnosis of an underrecognised manifestation of chronic cannabis abuse. World J Gastroenterol 2009; 15(10): 1264-1266.
95. Lee MH, Hancox RJ. Effects of smoking cannabis on lung function. Expert Rev Respir Med 2011; 5(4): 537-546; quiz 47.
96. Tessmer A, Berlin N, Sussman G, Leader N, Chung EC, Beezhold D. Hypersensitivity reactions to marijuana. Ann Allergy Asthma Immunol 2012; 108(4): 282-284.
97. Van Hoozen BE, Cross CE. Marijuana. Respiratory tract effects. Clin Rev Allergy Immunol 1997; 15(3): 243-269.
98. Tetrault JM, Crothers K, Moore BA, Mehra R, Concato J, Fiellin DA. Effects of marijuana smoking on pulmonary function and respiratory complications: a systematic review. Arch Intern Med 2007; 167(3): 221-228.
99. Hancox RJ, Poulton R, Ely M, et al. Effects of cannabis on lung function: a population-based cohort study. Eur Respir J 2010; 35(1): 42-47.
100. Reid PT, Macleod J, Robertson JR. Cannabis and the lung. J R Coll Physicians Edinb 2010; 40(4): 323-328; quiz 33-4.
101. Brambilla C, Colonna M. Cannabis: the next villain on the lung cancer battlefield? Eur Respir J 2008; 31(2): 227-228.
102. Aldington S, Harwood M, Cox B, et al. Cannabis use and risk of lung cancer: a case-control study. Eur Respir J 2008; 31(2): 280-286.
103. Pratap B, Korniyenko A. Toxic effects of marijuana on the cardiovascular system. Cardiovasc Toxicol 2012; 12(2): 143-148.
104. Jones RT. Cardiovascular system effects of marijuana. J Clin Pharmacol 2002; 42(11 Suppl): 58S-63S.
105. Singh NN, Pan Y, Muengtaweeponsa S, Geller TJ, Cruz-Flores S. Cannabis-related stroke: case series and review of literature. J Stroke Cerebrovasc Dis 2012; 21(7): 555-560.
106. Cottencin O, Karila L, Lambert M, et al. Cannabis arteritis: review of the literature. J Addict Med 2010; 4(4): 191-196.
107. Tennstedt D, Saint-Remy A. Cannabis and skin diseases. Eur J Dermatol 2011; 21(1): 5-11.
108. Muniyappa R, Sable S, Ouwerkerk R, et al. Metabolic Effects of Chronic Cannabis Smoking. Diabetes Care 2013 Mar 25.
109. Bonnet U. Chronic cannabis abuse, delta-9-tetrahydrocannabinol and thyroid function. Pharmacopsychiatry 2013; 46(1): 35-36.
110. Bari M, Battista N, Pirazzi V, Maccarrone M. The manifold actions of endocannabinoids on female and male reproductive events. Front Biosci 2011; 16: 498-516.
111. Hayatbakhsh MR, Flenady VJ, Gibbons KS, et al. Birth outcomes associated with cannabis use before and during pregnancy. Pediatr Res 2012; 71(2): 215-219.
112. Wu CS, Jew CP, Lu HC. Lasting impacts of prenatal cannabis exposure and the role of endogenous cannabinoids in the developing brain. Future Neurol 2011; 6(4): 459-480.
113. Karila L, Cazas O, Danel T, Reynaud M. Short- and long-term consequences of prenatal exposure to cannabis. J Gynecol Obstet Biol Reprod (Paris) 2006; 35(1): 62-70.
114. Gray KA, Day NL, Leech S, Richardson GA. Prenatal marijuana exposure: effect on child depressive symptoms at ten years of age. Neurotoxicol Teratol 2005; 27(3): 439-448.
115. Gray TR, Eiden RD, Leonard KE, Connors GJ, Shisler S, Huestis MA. Identifying prenatal cannabis exposure and effects of concurrent tobacco exposure on neonatal growth. Clin Chem 2010; 56(9): 1442-1450.
116. Feng BJ, Khyatti M, Ben-Ayoub W, et al. Cannabis, tobacco and domestic fumes intake are associated with nasopharyngeal carcinoma in North Africa. Br J Cancer 2009; 101(7): 1207-1212.
117. Aldington S, Williams M, Nowitz M, et al. Effects of cannabis on pulmonary structure, function and symptoms. Thorax 2007; 62(12): 1058-1063.
118. Voirin N, Berthiller J, Benhaim-Luzon V, et al. Risk of lung cancer and past use of cannabis in Tunisia. J Thorac Oncol 2006; 1(6): 577-579.
119. Berthiller J, Straif K, Boniol M, et al. Cannabis smoking and risk of lung cancer in men: a pooled analysis of three studies in Maghreb. J Thorac Oncol 2008; 3(12): 1398-1403.
120. Aldington S, Harwood M, Cox B, et al. Cannabis use and cancer of the head and neck: case-control study. Otolaryngol Head Neck Surg 2008; 138(3): 374-380.
121. Calabria B, Degenhardt L, Hall W, Lynskey M. Does cannabis use increase the risk of death? Systematic review of epidemiological evidence on adverse effects of cannabis use. Drug Alcohol Rev 2010; 29(3): 318-330.